Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates

Growth Hormone Deficiency Clinical Trial

Official title:

Effects of Low Dose Growth Hormone (GH) Therapy on Insulin Sensitivity, Adipocyte Insulin-like Growth Factor-I (IGF-I) and IGF-I/Insulin Receptor Density and Regulation of Cortisol Metabolism in GH Deficient Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00517062
• Other study ID #: IRB1844
• Status: Completed
• Phase: Phase 0
• First received: August 15, 2007
• Last updated: May 2, 2012
• Start date: January 2006
• Est. completion date: January 2012

Study information

• Verified date: May 2012
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Study hypothesis:

Growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity in adults with GH deficiency.

Study aims:

The purpose of this study is to determine the mechanism of how low dose GH treatment affects the body's sensitivity to insulin actions and whether this low GH dose can affect the body's handling of steroid hormone levels (cortisol clearance) in adults with GH deficiency.

Study design:

Men and women with confirmed GH deficiency, but not recently been on GH treatment will be invited to participate in this study. The subjects will be assessed at the initial visit to ascertain their suitability before further participating in the study. If suitable, an equal number of men and women will be randomized to receive either low dose GH or placebo injection for 3 months. Before, during and after treatment, the subjects will be assessed at regularly with blood tests, scans and fat biopsies. At the first and final visit, testing will include scans to measure the amount of whole body fat and fat in the stomach area, muscle, and liver; blood tests to measure levels of cortisol, and fat tissue (taken from a biopsy) analysis to measure the density of IGF-I in the muscle; whereas blood tests to examine insulin sensitivity will also be collected. This study will use Genotropin and Genotropin pen devices, and the the data will be analyzed using a computer statistical program where the identity of the subjects will be coded to maintain confidentiality.

Description:

The study will be double-blinded. One hundred subjects will be screened for eligibility initially, and 24 subjects will be enrolled with 12 subjects being randomized to receive the low GH dose (0.1 mg/day) treatment and 12 subjects to receive Placebo treatment for 3 months, allowing a 10% drop-out rate. The subjects will be taught by either by the Endocrine Nurse Specialists to self-administer the GH by subcutaneous injections using a Genotropin pen device.

Visit 1, Initial Screening Assessment (as out-patient)

• Physical examination, weight, height, and waist circumference measurements

• Fasting blood glucose levels

Visit 2, Baseline Assessment (as in-patient)

• Physical examination, weight, height, and waist circumference measurements

• Fasting blood tests for glucose, insulin, C-peptide, free IGF-I, total IGF-I, IGF-2, IGFBPs -1 and -3, non-esterified fatty acid and lipid profiles

• MRS, abdominal CT and DEXA scans

• One-step 3-hour hyperinsulinaemic euglycaemic clamp

• Cortisol production rates and urine cortisol collections

• Fat biopsies will be taken at the end of the assessment of cortisol production rates

Visit 3, Interim Assessment (Month 1) (as out-patient)

• Documentation of any adverse effects

• Fasting blood tests for glucose, insulin, C-peptide, free IGF-I, total IGF-I, IGF-2, IGFBPs -1 and -3

Visit 4, Final Assessment (Month 3) (as in-patient)

• Physical examination, weight, height, and waist circumference measurements

• Fasting blood tests for glucose, insulin, C-peptide, free IGF-I, total IGF-I, IGF-2, IGFBPs -1 and -3, non-esterified fatty acid and lipid profiles

• MRS, abdominal CT and DEXA scans

• One-step 3-hour hyperinsulinaemic euglycaemic clamp

• Cortisol production rates and urine cortisol collections

• Fat biopsies will be taken at the end of the assessment of cortisol production rates

Any extra blood remaining from the samples of blood drawn may be banked indefinitely with confidential identifiers, and may be given to researchers in the future to examine for other potential causes of diabetes and heart diseases in adults. These blood samples, however, will not be used for genetic studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age range 18 to 75 years

• BMI should not exceed 40 kg/m2

• Confirmed GH deficient with at least one provocative test, e.g. insulin tolerance test and/ or GHRH/arginine

• Not received any GH therapy within last 6 months

• On a stable standardized hydrocortisone replacement dose regimen (twice a day at 8 AM and 4 PM),

• If any other pituitary hormone deficiencies are present, patient must be on optimal pituitary hormone replacement therapy, e.g. Thyroxine, testosterone and oestrogen replacement

• Normal renal and hepatic function

• Prepared to self-inject

Exclusion Criteria:

• Untreated or subclinically hypo/hyperthyroid

• Untreated or subclinically treated hypocortisolism

• Type 1 or 2 diabetes mellitus

• Subjects with evidence of nephropathy from any cause

• Subjects with evidence of retinopathy from any cause

• Any other medical illnesses that may affect the interpretation of the results

• Pregnant

• Emotional/social instability likely to prejudice study completion

• Previous history of known malignancy

• Recurrent or severe unexplained hypoglycaemia

• Known or suspected drug/alcohol abuse

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dwarfism, Pituitary
• Growth Hormone Deficiency
• Insulin Resistance

Intervention

Drug:
• Growth hormone (Genotropin)
Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
• Placebo
Placebo self-injected once a day subcutaneously at bedtime.

Locations

Country	Name	City	State
United States	Oregon Health and Science University	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Oregon Health and Science University

Country where clinical trial is conducted

United States, 

References & Publications (3)

Yuen K, Frystyk J, Umpleby M, Fryklund L, Dunger D. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults. J Clin Endocrinol Metab. 2004 Aug;89(8):3956-64. — View Citation

Yuen K, Wareham N, Frystyk J, Hennings S, Mitchell J, Fryklund L, Dunger D. Short-term low-dose growth hormone administration in subjects with impaired glucose tolerance and the metabolic syndrome: effects on beta-cell function and post-load glucose tolerance. Eur J Endocrinol. 2004 Jul;151(1):39-45. — View Citation

Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE, Fryklund L, Murgatroyd PR, Dunger DB. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf). 2005 Oct;63(4):428-36. Erratum in: Clin Endocrinol (Oxf). 2005 Nov;63(5):599. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in insulin sensitivity (from the hyperinsulinemic euglycemic clamp		3 months	Yes
Secondary	Changes in fat IGF-I and IGF-I/insulin hybrid receptor density and body composition.		3 months	Yes

External Links

•   American Endocrine Society